松本 一宏 (マツモト カズヒロ)

Matsumoto, Kazuhiro

写真a

所属(所属キャンパス)

医学部 泌尿器科学教室 (信濃町)

職名

専任講師(有期)

メールアドレス

メールアドレス

経歴 【 表示 / 非表示

  • 2001年05月
    -
    2002年05月

    慶應義塾大学医学部

  • 2002年06月
    -
    2003年05月

    東京都済生会中央病院

  • 2003年06月
    -
    2004年05月

    東京医科大学医学科

  • 2004年06月
    -
    2007年04月

    大田原赤十字病院

  • 2005年05月
    -
    2006年05月

    慶應義塾大学医学部

全件表示 >>

学歴 【 表示 / 非表示

  • 1995年04月
    -
    2001年03月

    慶應義塾大学, 医学部

    大学, 卒業

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾, 論文, 2019年03月

    根治的前立腺全摘除術後の適切なフォロー アップスケジュールの確立

免許・資格 【 表示 / 非表示

  • 医師免許, 2001年05月

  • 日本泌尿器科学会専門医, 2006年04月

  • 日本泌尿器科学会指導医, 2011年04月

  • 日本癌治療認定医機構認定医, 2011年04月

  • 泌尿器腹腔鏡技術認定医, 2012年04月

全件表示 >>

 

研究キーワード 【 表示 / 非表示

  • 前立腺がん

  • 尿路上皮がん

  • 後腹膜軟部腫瘍

 

論文 【 表示 / 非表示

  • Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer

    Ogihara K., Kikuchi E., Okazaki S., Hagiwara M., Takeda T., Matsumoto K., Kosaka T., Mikami S., Saya H., Oya M.

    Cancer Science (Cancer Science)  110 ( 4 ) 1431 - 1441 2019年04月

    ISSN  13479032

     概要を見る

    © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. The prognostic role of CD44v9, a variant isoform of CD44 and a new cell surface marker of cancer stem cells, remains unclear in bladder cancer (BC) patients. Furthermore, limited information is available on the functional role of sulfasalazine (SSZ), which could modulate the CD44v9-xCT system in order to enhance cisplatin (CDDP)-induced cytotoxicity and inhibit the metastatic potential of BC. CD44v9 protein expression was examined immunohistochemically in 63 muscle invasive BC (MIBC) patients who underwent radical cystectomy. CD44v9 expression was independently associated with disease recurrence and cancer-specific death in MIBC. Cytotoxic effects, glutathione levels, and reactive oxygen species production by SSZ and CD44v9 and phospho-p38 MAPK protein expression by SSZ with or without CDDP were assessed in MBT-2V cells with highly metastatic potential. Sulfasalazine exerted cytotoxic effects against MBT-2V cells by inhibiting glutathione levels and inducing the production of reactive oxygen species. Sulfasalazine in combination with CDDP appeared to exert strong cytotoxic effects against MBT-2V cells by inhibiting CD44v9 expression and upregulating phospho-p38 MAPK expression. The inhibitory effects of SSZ with or without CDDP were also investigated using an MBT-2V lung metastatic model. In the murine lung metastatic BC model, SSZ significantly prolonged animal survival. Furthermore, the combination of SSZ with CDDP exerted stronger inhibitory effects on the establishment of lung tumor nodules than SSZ or CDDP alone. CD44v9 expression could be a clinical biomarker for predicting poor outcomes in MIBC patients. Sulfasalazine in combination with CDDP has potential as a novel therapy against metastatic BC.

  • The clinical implication of gamma globulin levels in patients with nonmuscle-invasive bladder cancer

    Niwa N., Matsumoto K., Ide H.

    Urologic Oncology: Seminars and Original Investigations (Urologic Oncology: Seminars and Original Investigations)  37 ( 4 ) 291.e1 - 291.e7 2019年04月

    ISSN  10781439

     概要を見る

    © 2019 Objective: The production of antibody, also referred immunoglobulin, is the principal functions of B cells. Gamma globulin fraction determined by serum protein electrophoresis is composed almost entirely of immunoglobulin. This study aimed to investigate the association between gamma globulin level and oncological outcomes in patients with nonmuscle-invasive bladder cancer (NMIBC). Patients and methods: A total of 274 patients with NMIBC who underwent transurethral surgery between 2000 and 2015 were identified. One hundred forty-four patients (52.6%) had received adjuvant intravesical bacillus Calmette-Guérin. Gamma globulin fraction (%) was determined by serum protein electrophoresis, and gamma globulin level (mg/dl) was calculated by multiplying the total protein level (mg/dl) by the gamma globulin fraction (%). The association between gamma globulin levels and oncological outcomes was statistically evaluated. Results: During a median follow-up period of 39 months, 99 (36.1%) patients experienced at least 1 tumor recurrence and 16 (5.8%) patients had disease progression. The median (interquartile range) gamma globulin level was 1.2 (1.0–1.3) mg/dl. Recurrence-free survival rate of patients with gamma globulin levels of ≥1.4 mg/dl was significant lower than that of patients with gamma globulin levels of <1.4 mg/dl (P < 0.01). There was no significant difference in progression-free survival between the 2 groups (P = 0.17). Multivariate analysis revealed that gamma globulin level of ≥1.4 mg/dl is significantly associated with higher recurrence rate (hazard ratio = 1.83, P < 0.01). Conclusion: Gamma globulin level is significantly associated with tumor recurrence. Our results suggest that B cell immunity may be involved in tumor recurrence in patients with NMIBC.

  • Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.

    Shigeta K, Kosaka T*, Hongo H, Yanai Y, Matsumoto K, Morita S, Mizuno R, Shinojima T, Kikuchi E, Oya M.

    Int J Clin Oncol. 2019年

    研究論文(学術雑誌), 査読有り

  • Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.

    Takamatsu K, Mizuno R*, Tanaka N, Takeda T, Morita S, Matsumoto K, Kosaka T, Shinojima T, Kikuchi E, Asanuma H, Oyama M, Mikami S, Oya M.

    Int J Clin Oncol. 2019年

    研究論文(学術雑誌), 査読有り

  • Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer

    Matsumoto K., Akita H., Narita K., Hashiguchi A., Takamatsu K., Takeda T., Kosaka T., Mizuno R., Kikuchi E., Oya M., Jinzaki M.

    Prostate Cancer and Prostatic Diseases (Prostate Cancer and Prostatic Diseases)  2019年

    ISSN  13657852

     概要を見る

    © 2019, Springer Nature America, Inc. Background: Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of EPE is controversial. Methods: We retrospectively analyzed the records of 233 consecutive patients who underwent preoperative MRI and radical prostatectomy. We designated their tumors as anterior or posterior, and evaluated the correlation between the TCL measured by MRI and microscopic EPE in the radical prostatectomy specimen. Then, we created the predicted probability curves for EPE versus TCL for anterior and posterior prostate cancer. Results: There were 109 patients (47%) with an anterior tumor and 124 patients (53%) with a posterior tumor. Postoperative pathological analysis confirmed pT3 in 18 patients (17%) with an anterior tumor and in 53 patients (43%) with a posterior tumor. Multivariate analysis demonstrated that the zonal origin of the tumor was an independent predictive factor for EPE. We developed separate probability curves of EPE versus TCL for anterior and posterior prostate cancer, which revealed that anterior tumors were less likely to invade the extraprostatic tissues. Among patients whose TCL was 10–20 mm, 9/32 patients (28%) with an anterior tumor had EPE compared with 24/45 patients (53%) with a posterior tumor (p = 0.036). The decision curve of this EPE predictive model had high clinical efficacy. Conclusions: Our results indicate that anterior tumors have more favorable pathological characteristics than posterior tumors with the same TCL measured by MRI. We constructed two separate predicted probability curves for EPE after discriminating anterior and posterior tumors, which will be useful for decision making in clinical practice.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

研究発表 【 表示 / 非表示

  • 高齢者の表在性膀胱癌間じゃに対するBCG膀注の再発予防効果についての検討

    弓削和之、菊地栄次、松本一宏、宮嶋 哲、中川 健、大東貴志、中島 淳、大家基嗣

    第96回日本泌尿器科学会総会 (横浜) , 2008年04月, 口頭(一般)

  • 放射線照射後の膀胱穿孔に伴う急性腎不全の一例

    伊藤祐二郎、松本一宏、金子 剛、井手広樹、水野隆一、大東貴志、村井 勝

    日本泌尿器科学会東京地方会 (第582回) , 2006年06月, 口頭(一般)

競争的資金等の研究課題 【 表示 / 非表示

  • ドラッグ・リポジショニングを用いた、膀胱癌に対する抗癌剤注入療法の効果増強

    2018年09月
    -
    2019年08月

    第一三共奨学寄付プログラム

  • ドラッグ・リポジショニングを用いた、筋層非浸潤性膀胱癌の抗癌剤注入療法耐性の克服

    2018年08月
    -
    2019年07月

    サノフィ・ジャパングループ教育研究助成

  • ドラッグ・リポジショニングを用いた、筋層非浸潤性膀胱癌に対する新規膀胱内注入療法の開発

    2018年05月
    -
    2019年04月

    慶應義塾大学学事振興資金

  • ドラッグ・リポジショニングを用いた、膀胱癌に対する新規膀胱内注入療法

    2018年04月
    -
    2021年03月

    文部科学省・日本学術振興会, 文部科学省科学研究費補助金(基盤研究C), 松本 一宏, 補助金,  代表

  • ドラッグ・リポジショニングを用いた、筋層非浸潤性膀胱癌に対する新規膀胱内注入療法の開発

    2018年04月
    -
    2019年03月

    第12回日本泌尿器科学会ヤングリサーチグラント

全件表示 >>

受賞 【 表示 / 非表示

  • 慶應義塾大学医学部三四会奨励賞

    2015年06月

  • IJU Reviewers of the Year 2013

    2014年04月

  • 第49回癌治療学会優秀演題賞

    2011年11月

  • 第45回癌治療学会優秀演題賞

    2007年10月

 

担当授業科目 【 表示 / 非表示

  • 泌尿器科学講義

    2020年度

  • 泌尿器科学講義

    2019年度